2024-08-23-上交所-健康元药业集团股份有限公司2024年半年度报告（英文版）_277页_4mb

报告摘要

Joincare 2024 Interim Report Summary

Core Information

Mission and Vision

Mission: For the Health For the Future
Vision: Diligently make high-quality and innovative drugs
Core Values: Putting people first, Valuing workmanship and quality, Pursuing innovation and truth, Promoting cooperation and sharing

Important Notice

The Board of Directors, Board of Supervisors, and senior management have affirmed the truthfulness, accuracy, and completeness of the interim report.
All directors attended the Board meeting.
The interim report is unaudited.
The financial statements are signed and sealed by the person-in-charge of the Company, the person-in-charge of the accounting work, and the head of the accounting department.
No profit distribution plan or capital reserve conversion plan was approved during the reporting period.
The report includes forward-looking statements, which do not constitute substantive undertakings to investors.
No significant non-operating use of funds by the controlling shareholder or related parties.
No violation of prescribed decision-making procedures for external guarantees.
All directors have warranted the truthfulness, accuracy, and completeness of the report.

Significant Risk Warnings

There are no exceptionally significant risks that will have a material impact on the Company's operations during the reporting period.
The Company has outlined potential risks and countermeasures, including industry policy risk, market risk, safety and environmental protection risk, raw material price and supply risk, and R&D risk.
For more details, refer to the "Potential risks" section in Chapter 3 Management Discussion and Analysis.

Company Profile and Major Financial Indicators

Contact Information

Board Secretary: Zhao Fengguang (赵凤光)
Securities Affairs Representatives: Li Hongtao (李洪涛), Luo Xiao (罗逍)
Address: Joincare Pharmaceutical Group Building, No. 17, Langshan Road, North District, Hi-tech Zone, Nanshan District, Shenzhen
Postal code: 518057
Website: http://www.joincare.com
Email: joincare@joincare.com

Stock Profile

A Share: Listed on Shanghai Stock Exchange, Stock abbreviation: 健康元, Stock code: 600380
GDR: Listed on SIX Swiss Exchange, Stock abbreviation: Joincare Pharmaceutical Group Industry Co., Ltd., Stock code: JCARE

Principal Accounting Data and Financial Indicators

Reporting Period (Jan–Jun 2024)

Revenues: RMB8,234.63 billion (down 5.56% YoY)
Net profit attributable to Shareholders of the listed company: RMB776.42 billion (down 4.78% YoY)
Net profit after deducting extraordinary gain or loss: RMB761.91 billion (down 2.54% YoY)
Net cash flow from operating activities: RMB1,737.30 billion (up 38.19% YoY)
Net assets attributable to Shareholders of the listed company: RMB14,312.14 billion (up 4.04% YoY)
Total assets: RMB36,496.08 billion (up 0.38% YoY)

Financial Indicators

Basic earnings per share: RMB0.4158 (down 2.49% YoY)
Diluted earnings per share: RMB0.4154 (down 2.28% YoY)
Basic earnings per share after extraordinary gain or loss: RMB0.4080 (down 0.20% YoY)
Weighted average return on net assets: 5.50% (down 0.79 percentage points YoY)
Weighted average return on net assets after extraordinary gain or loss: 5.39% (down 0.64 percentage points YoY)

Principal Businesses and Products

I. Chemical Pharmaceuticals

Respiratory: Tobramycin Inhalation Solution (健可妥), Levosalbutamol Hydrochloride Nebulizer Solution (丽舒同), Budesonide Suspension for Inhalation (雾舒), Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation (健忘畅)
Gastroenterology: Ilaprazole Sodium for Injection (壹顺安), Ilaprazole Enteric-Coated Tablets (壹丽安), Bismuth Potassium Citrate Capsules (丽珠得乐), Bismuth Potassium Citrate Tablets/Metronidazole Tablets/Clarithromycin Tablets (丽珠维三联)
Assisted Reproduction: Leuprolen Acetate Microspheres for Injection (贝依), Triptorelin Acetate Microspheres for Injection (维宝宁), Urofoltolropin for Injection (丽申宝), Cetorelix Acetate for Injection (丽欣曲)
Anti-infection: Meropenem for Injection (倍能), Voriconazole for Injection (丽福康), Imipenem and Cilastatin Sodium for Injection (速能)
Psychiatry: Fluvoxamine Maleate Tablets (瑞必乐), Perosphrine Hydrochloride Tablets (康尔汀), Bionanserin Tablets (丽同效)

II. Biologics

Tocilizumab Injection: (Atvliia)
Recombinant SARS-CoV-2 Fusion Protein Bivalent Vaccine: (Prototype/Omicron XBB Variant)
Recombinant Human Choriogonadotropin alfa for Injection: (海豚皂)
Mouse Nerve Growth Factor for Injection: (丽康乐)
Bifidobacterium Viable Capsule: (丽珠场乐)

III. Traditional Chinese Medicine

Cold medicine Anti-Viral Granules
Anti-tumour medicine Shenqi Fuzheng Injection

IV. Chemical APIs and Intermediates

Human drugs: 7-ACA, Daptomycin, Dalbavancinee, Vancomycin, Mevastatin, Acarbose
Veterinary drugs: Milbemycin Oxime, Moxidectin

V. Diagnostic Reagents and Equipment

Mycoplasma pneumoniae IgM Antibody Test: (Colloidal gold method)
Antinuclear Antibody Test Kit: (Magnetic Bar code)
Nucleic Acid Test Kit for HIV-1: (Real-Time PCR)
Interferon-Gamma Release Assays (IGRA) Test Kit: (Chemiluminescence Immunoassay)

VI. Health Care Products

Taitai Oral Liquid
Jingxin Oral Liquid
Eagle's American Ginseng Tea

Business Model

R&D: Combines independent R&D, external introduction, and cooperative development. Focuses on innovative drugs and high-barrier complex formulations.
Procurement: Emphasizes effectiveness, quality, and cost. Has long-term partnerships with suppliers and strict quality standards.
Production: Follows market demand-oriented approach. Adheres to GMP standards and has a sound quality management system.
Sales:
- Drug formulation products: Sold through drug distribution enterprises to hospitals, clinics, and retail pharmacies.
- APIs and intermediates: Sold to large pharmaceutical manufacturers. Pricing is determined by production costs, inventory levels, industry competition, and market trends. Sales methods include direct sales and distribution channels in both domestic and foreign markets.

Conclusion

Joincare is a diversified pharmaceutical company with a focus on R&D, production, and sales of pharmaceutical and health care products. It has a strong presence in chemical pharmaceuticals, biologics, TCM, APIs, and diagnostic reagents. The company emphasizes innovation, quality, and cooperation in its operations and has a well-established business model. The financial performance for the first half of 2024 showed a slight decline in revenues and net profit but an increase in net cash flow from operating activities. The report highlights the company's commitment to transparency and risk management.

展开完整摘要